Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.
Expert Opin Biol Ther. 2011 Nov;11(11):1519-24. doi: 10.1517/14712598.2011.610788. Epub 2011 Aug 31.
Advanced malignancies that are refractory to standard chemotherapy have few treatment options. Conatumumab is an investigational, fully human monoclonal agonist antibody directed at human death receptor DR5, which is expressed in multiple advanced cancers.
The rationale for the use of conatumumab based on in vitro, in vivo, Phase I, and Phase II data will be discussed.
Conatumumab, at a dose of 20 mg/kg every 2 weeks, has demonstrated acceptable safety and tolerability in patients with advanced tumors based on available and published data. Further clinical trials are underway evaluating the use of conatumumab in combination with chemotherapeutic and targeted agents.
对标准化疗有抗性的晚期恶性肿瘤的治疗选择有限。康奈妥单抗是一种研究用的、全人源的、针对人死亡受体 DR5 的单克隆激动剂抗体，DR5 在多种晚期癌症中表达。
将根据体外、体内、I 期和 II 期数据讨论使用康奈妥单抗的基本原理。
根据现有和已发表的数据，在剂量为 20mg/kg、每 2 周给药 1 次的情况下，康奈妥单抗在晚期肿瘤患者中表现出可接受的安全性和耐受性。正在进行进一步的临床试验，以评估康奈妥单抗与化疗药物和靶向药物联合使用的效果。
